Double-Duty drugs: testing a Two-Pronged attack on lung cancer before and after surgery
NCT ID NCT04832854
Summary
This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab), given with or without standard chemotherapy, for people with certain stages of non-small cell lung cancer that could be removed by surgery. The goal was to see if giving these drugs both before surgery (to shrink the tumor) and after surgery (to prevent it from coming back) was safe and effective. The trial enrolled 50 participants but was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Columbia University
New York, New York, 10032-3725, United States
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, 15006, Spain
-
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, 08208, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, 28222, Spain
-
ICO L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Kantonsspital Baden
Baden, 5404, Switzerland
-
Kantonsspital Graubünden Medizin Onkologie
Chur, 7000, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
NYU Cancer Center
New York, New York, 10016, United States
-
Peter Maccallum Cancer Institute
Melbourne, Victoria, 3000, Australia
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
St. Vincent's Hospital
Gyeonggi-do, 16247, South Korea
-
Sunshine Coast University Hospital
Birtinya, Queensland, 4575, Australia
-
University of Southern California
Los Angeles, California, 90033, United States
-
UniversitätsSpital Zürich
Zurich, 8091, Switzerland
-
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Winthrop Univ Hospital
Mineola, New York, 11501, United States
Conditions
Explore the condition pages connected to this study.